Brought to you by 
Insiders fund Gamida Cell’s $10mm Series E financing
30 May 2012
Executive Summary
Gamida Cell Ltd. (stem cell therapies) completed a $10mm Series E financing from all major existing backers (possibly including Elbit Imaging, Clal Biotechnology Industries, Israel HealthCare Ventures, Teva Pharmaceutical, Amgen, Denali Ventures, and Auriga Ventures). The money will fund future global marketing of the company’s allogeneic stem cell candidate StemEx, which is in Phase III for leukemia and lymphoma as an alternate to bone marrow transplantation. The US launch is planned for next year. The therapeutic, an expanded population of stem/progenitor cells combined with nonexpanded cells from the same umbilical cord unit, was developed through a joint venture Gamida formed with Teva in 2005. Series E funds will also support a clinical trial evaluating Gamida’s Phase I/II NiCord for sickle cell disease and thalassemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Insiders fund Gamida Cell’s $10mm Series E financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice